Sipuleucel-T is a cell product that was developed by culturing DCs with a tumor antigen (prostatic acid phosphatase (PAP) fusion protein) and was found to prolong survival by approximately 4 months in a phase III trial [86]. The gene discussed is ACP3; the disease is neoplasm.